INTEGRAL DIAGNOSTICS LIMITED (IDX)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

IDX

IDX - INTEGRAL DIAGNOSTICS LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 5.14
Index: ASX300 | ALL-ORDS

Integral Diagnostics is an Australian healthcare services company providing diagnostic imaging services to medical practitioners in Australia and New Zealand. It has been a listed company since 2015.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$2.61

14 Oct
2025

-0.040

OPEN

$2.62

-1.51%

HIGH

$2.66

780,525

LOW

$2.60

TARGET
$3.567 36.7% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
ACL . AHX . ALC . BMT . DOC . EBO . HLS . M7T . MDR . MPL . MVF . NHF . PSQ . RHC . SHL .
FNARENA'S MARKET CONSENSUS FORECASTS
IDX: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx 1.5 13.3 xxx
DPS (cps) xxx 6.5 8.5 xxx
EPS Growth xxx N/A 100.0% xxx
DPS Growth xxx 12.1% 31.3% xxx
PE Ratio xxx N/A 19.7 xxx
Dividend Yield xxx N/A 3.3% xxx
Div Pay Ratio(%) xxx 427.6% 64.3% xxx

Dividend yield today if purchased 3 years ago: 2.66%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 2.49

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 29/02 - ex-div 2.5c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx1.5
DPS All xxxxxxxxxxxxxxx6.5
Sales/Revenue xxxxxxxxxxxxxxx627.2 M
Book Value Per Share xxxxxxxxxxxxxxx186.2
Net Operating Cash Flow xxxxxxxxxxxxxxx73.8 M
Net Profit Margin xxxxxxxxxxxxxxx0.75 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx0.94 %
Return on Invested Capital xxxxxxxxxxxxxxx0.49 %
Return on Assets xxxxxxxxxxxxxxx0.43 %
Return on Equity xxxxxxxxxxxxxxx0.94 %
Return on Total Capital xxxxxxxxxxxxxxx5.90 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-1.4 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx20 M
Long Term Debt xxxxxxxxxxxxxxx565 M
Total Debt xxxxxxxxxxxxxxx585 M
Goodwill - Gross xxxxxxxxxxxxxxx802 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx52 M
Price To Book Value xxxxxxxxxxxxxxx1.36

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx59.8 M
Capex % of Sales xxxxxxxxxxxxxxx9.53 %
Cost of Goods Sold xxxxxxxxxxxxxxx489 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx82 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

3
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

27/08/2025

1

Outperform

$3.40

30.27%

Integral Diagnostics' FY25 result was in line with Macquarie’s expectations, with revenue up 6.7% year-on-year and margins expanding 70bps to 20.1%. Earnings (EBITDA) came in around 1% ahead of the broker's forecasts.

Australian revenue grew 7.3% and New Zealand 1.4% on a constant currency basis, with fees per exam up 5% from indexation and mix shift, explains the analyst.

Macquarie points to revenue tailwinds, with FY26 starting strongly at 7% growth on a like-for-like basis.

MRI deregulation from July 2025 and the national lung cancer screening program are expected to lift funding and utilisation, alongside expanded bulk billing eligibility driving referrals.

The broker expects margin expansion from merger cost synergies, now raised to $14m, supported by scale and teleradiology. 

The broker cuts its EPS forecasts acrosss FY26-28 by -9%, -9% and -3%, respectively, due to lower revenue and higher interest forecasts, with upgrades in FY29-FY30.

Macquarie raises its target price to $3.40 from $3.20 and retains an Outperform rating.

FORECAST
Macquarie forecasts a full year FY26 dividend of 8.00 cents and EPS of 13.30 cents.
Macquarie forecasts a full year FY27 dividend of 9.00 cents and EPS of 15.80 cents.

Ord Minnett

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Jarden

03/09/2025

1

Buy

$3.41

30.65%

Integral Diagnostics reported better-than-expected FY25 earnings, with net profit after tax assisted by lower depreciation, according to Jarden.

The outlook for FY26 relies on MRI deregulation, the National Lung Screening Program, the GP Bulk Billing program, as well as synergy capture and other factors, including slowing capex to -$45m-$55m from around -$65m.

Positively, labour costs have slowed into FY26, but any impacts will take time, commentary highlights, as will the spread of MRI deregulation benefits.

Jarden lowers its EPS forecasts by -7.3% for FY26 and -5.4% for FY27. Buy retained. Target falls to $3.41 from $3.45.

FORECAST
Jarden forecasts a full year FY26 dividend of 9.30 cents and EPS of 14.20 cents.
Jarden forecasts a full year FY27 dividend of 12.00 cents and EPS of 18.30 cents.
Access Extra Coverage Research History >

IDX STOCK CHART

FNArena News on IDX

1
Australian Broker Call *Extra* Edition – Oct 06, 2025

Oct 06 2025 - Daily Market Reports
2
Rudi’s View: August Results; Standouts, Turnarounds, Failures & Misfits

Sep 10 2025 - Rudi's View
3
In Case You Missed It – BC Extra Upgrades & Downgrades – 05-09-25

Sep 05 2025 - Weekly Reports
4
Rudi’s View: Catalyst Metals, Dexus, Neuren, Stockland, ResMed & More

Sep 04 2025 - Rudi's View
5
Australian Broker Call *Extra* Edition – Sep 03, 2025

Sep 03 2025 - Daily Market Reports

Latest Healthcare services News

1
Better Times Ahead For Sonic Healthcare?

Jun 20 2025 - Australia
2
The Significance Of Cosmetique’s ASX Listing

Feb 26 2025 - Small Caps
3
Building The No 3 Diagnostic Imaging Player

Jun 19 2024 - Small Caps
4
Capitol Health’s Higher Margin Outlook

Mar 13 2024 - Small Caps
5
Treasure Chest: Ramsay Health Care

Oct 26 2023 - Treasure Chest
6
Timing Seems Right For Alcidion Group

Jun 21 2023 - Small Caps
7
No Enthusiasm To Combine ACL & Healius

Mar 21 2023 - Australia
8
Dr Boreham’s Crucible: Alcidion

Dec 13 2022 - Small Caps
9
No Straight Covid-Relief For Ramsay Health Care

Nov 15 2022 - Australia
10
Dr Boreham’s Crucible: Mach7 Technologies

Nov 14 2022 - Small Caps